Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $16.2 million.

  • CytomX Therapeutics' Gains from Investment Securities rose 1103.27% to $16.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 1103.27%. This contributed to the annual value of $14.6 million for FY2024, which is 1245.17% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Gains from Investment Securities of $16.2 million as of Q3 2025, which was up 1103.27% from $16.4 million recorded in Q2 2025.
  • CytomX Therapeutics' Gains from Investment Securities' 5-year high stood at $16.8 million during Q1 2025, with a 5-year trough of $11.5 million in Q3 2021.
  • Its 5-year average for Gains from Investment Securities is $14.0 million, with a median of $14.3 million in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 2394.81% in 2022, then tumbled by 679.98% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Gains from Investment Securities (Quarter) stood at $12.2 million in 2021, then rose by 9.0% to $13.3 million in 2022, then dropped by 2.56% to $12.9 million in 2023, then rose by 12.45% to $14.6 million in 2024, then rose by 11.09% to $16.2 million in 2025.
  • Its Gains from Investment Securities stands at $16.2 million for Q3 2025, versus $16.4 million for Q2 2025 and $16.8 million for Q1 2025.